All In Biotech

NDA 208073 · Bausch and Lomb INC

Xiidra

Lifitegrast · Ophthalmic · Lymphocyte Function-Associated Antigen-1 Antagonist

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Apr 4, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Jul 11, 2016

Approved uses

1

Original approval plus efficacy supplements

Registered trials

34

6 Phase 3, 2 recruiting

FAERS reports

16,505

2,977 serious, 298 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 18, 2025.

Xiidra ® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of the signs and symptoms of dry eye disease (DED). Xiidra (lifitegrast ophthalmic solution) 5% is a lymphocyte function-associated antigen-1 (LFA-1) antagonist indicated for the treatment of the signs and symptoms of dry eye disease (DED). ( 1 )

Mechanism: Lifitegrast binds to the integrin LFA-1, a cell surface protein found on leukocytes and blocks the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1). ICAM-1 may be overexpressed in corneal and conjunctival tissues in DED. LFA-1/ICAM-1 interaction can contribute to the formation of an immunological synapse resulting in T-cell activation and migration to target tissues. In vitro studies demonstrated that lifitegrast may inhibit T-cell adhesion to ICAM-1 in a human T-cell line and may inhibit secretion of inflammatory cytokines in human peripheral blood...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 11, 2016 Original approval · Type 1 - New Molecular Entity · priority review NovelReviewLetterLabel
1 products under this application
  • XIIDRA · LIFITEGRAST 5% · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Lifitegrast" as an intervention, any sponsor and status, largest first.

All 34 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • eye irritation2,780
  • vision blurred2,679
  • drug ineffective1,629
  • eye pain1,460
  • instillation site pain1,283
  • dry eye1,187
  • dysgeusia1,118
  • instillation site reaction1,019
  • ocular hyperaemia707
  • lacrimation increased636
  • headache629
  • visual impairment587

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20154
2016630
20171,846
20181,538
20191,189
20201,976
20212,129
20222,489
20231,922
20241,097
2025985
2026700

Recalls

2 FDA enforcement reports for this application.

  • May 10, 2022 · Class III · Terminated

    Failed Impurities/Degradation Specifications.

  • May 10, 2022 · Class III · Terminated

    Failed Impurities/Degradation Specifications.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Xiidra (Lifitegrast)

2024 spending

$505M

Beneficiaries

166,361

477,354 claims

Per beneficiary

$3,038

$11.19 per unit

View as table
YearSpending
2020$28,032,943
2021$261,124,341
2022$332,509,806
2023$472,699,911
2024$505,334,180

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 15 on PubMed

Sponsor: Bausch and Lomb INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.